Evotec AG (EVTCY) Receives Consensus Rating of “Buy” from Brokerages
Evotec AG (NASDAQ:EVTCY) has been given a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company.
Zacks has also assigned Evotec AG an industry rank of 115 out of 265 based on the ratings given to related companies.
EVTCY has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Evotec AG from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Friday, August 25th. DZ Bank AG reiterated a “sell” rating on shares of Evotec AG in a research note on Thursday, August 17th.
ILLEGAL ACTIVITY NOTICE: “Evotec AG (EVTCY) Receives Consensus Rating of “Buy” from Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/11/04/evotec-ag-evtcy-receives-consensus-rating-of-buy-from-brokerages.html.
Evotec AG (NASDAQ:EVTCY) traded up $2.78 during trading on Friday, reaching $41.62. 1,183 shares of the company traded hands, compared to its average volume of 7,364. Evotec AG has a 12-month low of $11.03 and a 12-month high of $52.82.
Evotec AG (NASDAQ:EVTCY) last announced its earnings results on Thursday, August 10th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.03). The firm had revenue of $58.52 million for the quarter, compared to analyst estimates of $50.06 million.
Evotec AG Company Profile
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.